

Serum aims high revenue growth through new launches

01 November 2017 | News

The company has launched Rotasiil vaccine and Rabishield.



Serum Institute of India, at Pune, aims to achieve revenues of Rs 10,000 crore in the next five years period through new launches and expanding footprints in Europe and US.

The company is developing vaccine and drug for dengue fever. It has commenced first phase of trials in Singapore and hopes to launch vaccine in 2020.

The company has also launched Rotasiil vaccine and Rabishield, Rabies monoclonal antibody which will help in achieving 30 per cent growth this year. The availability of Rotasiil and Rabishield worldwide will help reduce deaths caused due to Rotavirus and Rabies which cause fatal diseases.

Rabishield has been developed in research partnership with Massachusetts Medical School, US. Rabishield will be 25 per cent cheaper than the existing rabies immunoglobulins, it would meet the needs of the poor countries

Serum intends to launch more vaccines in coming years. It is the world's largest manufacturer of vaccines and sells about 1.3 billion doses a year globally across 147 countries.